Clearmind Medicine

(NASDAQ) CMND

Current Price$1.99

Market Cap$2.96M

Since IPO (2021)-100%

5 YearN/A

1 Year-100%

1 Month-46%

Clearmind Medicine last closing stock price
Metric	Price	Date
Last close	USD 1.82	2026-07-15

Clearmind Medicine stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-13.33%	USD 2.10	2026-07-08
1 month	-45.99%	USD 3.37	2026-06-15
3 month	-78.19%	USD 8.35	2026-04-16
Year to date	-89.94%	USD 18.10	2025-12-31
1 year	-99.53%	USD 388.80	2025-07-15
3 year	-99.97%	USD 5,370.00	2023-07-14
Since inception	-100%	USD 251,097.99	2021-08-16

Clearmind Medicine Financials at a Glance

Market Cap

$2.96M

Revenue (TTM)

$0.00

Net Income (TTM)

-$7.90M

EPS (TTM)

-$185.93

P/E Ratio

-0.01

Dividend

$0.00

Beta (Volatility)

0.34 (Low)

Dividend

$0.00

Beta (Volatility)

0.34 (Low)

Price

$1.99

Volume

1,472,475.202

Open

$1.83

Price

$1.99

Volume

1,472,475.202

Open

$1.83

Previous Close

$1.99

Daily Range

$1.74 - $2.25

52-Week Range

$1.74 - $524.00

Estimated Earnings Date

Jun 15, 2026

Dividend

$0.00

Beta (Volatility)

0.34 (Low)

Price

$1.99

Volume

1,472,475.202

Open

$1.83

Previous Close

$1.99

Daily Range

$1.74 - $2.25

52-Week Range

$1.74 - $524.00

Estimated Earnings Date

Jun 15, 2026

CMND News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Clearmind Medicine

Clearmind Medicine Inc. is a development-stage company focused on innovative treatments for mental health and addiction. The company leverages unique psychedelic-based compounds to address unmet needs in these areas, aiming to transform how therapies are delivered. Their focus includes leveraging strategic partnerships and a skilled leadership team to navigate complex regulatory environments.

Products and Services

Development of psychedelic-based compounds for mental health therapy.

Special focus on addiction treatment with compounds like MEAI.

Collaborative strategies with research institutions for clinical trials.

What Makes Clearmind Medicine Inc. Special

Clearmind Medicine Inc. differentiates itself through its focus on psychedelic-based therapies for mental health and addiction. This approach draws on a strong research pipeline, expertise in pharmaceutical development, and strategic collaborations with leading research institutions.

Five Things You Need to Know

Clearmind Medicine is at a development stage, focusing on unique mental health solutions.

The company leverages psychedelic compounds, particularly MEAI, for addiction treatment.

Leadership combines expertise in pharmaceutical development and regulatory processes.

Strategic partnerships enhance innovation and clinical development progress.

The company aims to change perceptions and drive market adoption of psychedelic therapies.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Adi Zuloff-Shani, PhD

Website

www.clearmindmedicine.com

Headquarters

Vancouver, BC V6H 1A5, CA

CMND Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-138.23%

Return on Capital

-190.72%

Return on Assets

-54.40%

Earnings Yield

-100.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.96M

Shares Outstanding

1.49M

Volume

1.47M

Avg. Volume

2.39M

Financials (TTM)

Gross Profit

-$52.58K

Operating Income

-$8.09M

EBITDA

-$7.34M

Operating Cash Flow

-$6.76M

Capital Expenditure

$0.00

Free Cash Flow

-$6.76M

Cash & ST Invst.

$13.59M

Total Debt

$85.59K

Clearmind Medicine Performance Analysis

Clearmind Medicine annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-10-31	USD 0	N/A
2023	2023-10-31	USD 0	N/A
2024	2024-10-31	USD 0	N/A
2025	2025-10-31	USD 0	N/A

Clearmind Medicine sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-07-31	N/A
Q4	2025-10-31	N/A
Q1	2026-01-31	N/A
Q2	2026-04-30	N/A

Clearmind Medicine annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-10-31	USD -67,445.33	76.3%
2023	2023-10-31	USD -17,030.28	-74.7%
2024	2024-10-31	USD -678.00	-96.0%
2025	2025-10-31	USD -303.48	-55.2%

Clearmind Medicine sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-07-31	-58.1%
Q4	2025-10-31	51.0%
Q1	2026-01-31	-591.7%
Q2	2026-04-30	-104.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$13.90K

-16.1%

Gross Margin

0.00%

N/A

Market Cap

$2.96M

N/A

Market Cap/Employee

$739.05K

N/A

Employees

N/A

Net Income

-$2.05M

-161.0%

EBITDA

-$1.56M

-109.3%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$13.59M

+111.6%

Total Debt

$85.59K

+72.2%

Accounts Receivable

$551.69K

+120.2%

Inventory

$0.00

N/A

Long Term Debt

$44.35K

N/A

Short Term Debt

$41.24K

-17.0%

Return on Assets

-54.40%

N/A

Return on Invested Capital

-70.16%

N/A

Free Cash Flow

-$1.79M

-18.1%

Operating Cash Flow

-$1.79M

-18.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

TTNPTitan Pharmaceuticals, Inc.

TTNPTitan Pharmaceuticals, Inc.$2.34-11.36%

CNSPCNS Pharmaceuticals, Inc.

CNSPCNS Pharmaceuticals, Inc.$4.74+1.28%

SNGXSoligenix, Inc.

SNGXSoligenix, Inc.$0.36-3.31%

SILOSilo Pharma, Inc.

SILOSilo Pharma, Inc.$4.78-1.95%

XBIOXenetic Biosciences, Inc.

XBIOXenetic Biosciences, Inc.$2.81-3.10%

GRIGRI Bio, Inc.

GRIGRI Bio, Inc.$1.54-4.94%

JAGXJaguar Health, Inc.

JAGXJaguar Health, Inc.$1.34-31.54%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$15.60-0.00%

ATAIAtaiBeckley

ATAIAtaiBeckley$7.15+0.33%

NOKNokia

NOKNokia$10.38-0.08%

ONDSOndas

ONDSOndas$6.65-0.06%

INTCIntel

INTCIntel$96.98-0.06%

PATHUiPath

PATHUiPath$12.03+0.01%

TAT&T

TAT&T$21.98+0.03%

Questions About CMND

What is the current price of Clearmind Medicine?

Clearmind Medicine is trading at $1.99 per share.

What is the 52-week range for Clearmind Medicine?

Over the past 52 weeks, Clearmind Medicine has traded between $1.74 and $524.00.

How much debt does Clearmind Medicine have?

As of the most recent reporting period, Clearmind Medicine reported total debt of $85.59K.

How much cash does Clearmind Medicine have on hand?

Clearmind Medicine reported $11.42M in cash and cash equivalents in its most recent financial results.

What is Clearmind Medicine’s dividend yield?

Clearmind Medicine does not currently have a dividend yield.

Clearmind Medicine

Clearmind Medicine Financials at a Glance

CMND News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Clearmind Medicine

Products and Services

What Makes Clearmind Medicine Inc. Special

Five Things You Need to Know

CMND Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Clearmind Medicine Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CMND

What is the current price of Clearmind Medicine?

What is the 52-week range for Clearmind Medicine?

How much debt does Clearmind Medicine have?

How much cash does Clearmind Medicine have on hand?

What is Clearmind Medicine’s dividend yield?

Premium Investing Services